Luxna Biotech Co., Ltd.

  • EN
  • JP

Luxna Biotech Co., Ltd.

  • About
  • Oligonucleotide Therapeutics
  • Technology
  • Business Structure
  • News
  • Open Positions
  • Access
  • Contact
ルクサナバイオテク株式会社
  • About
  • Oligonucleotide Therapeutics
  • Technology
  • Business Structure
  • News
  • Open Positions
  • Access
  • Contact

Notice│ News

  1. HOME
  2. News
  3. Notice

Notice: Adoption of The 4th Cyclic Innovation for Clinical Empowerment(CiCLE) by Japan Agency for Medical Research and Development(AMED)

  • 2020/01/07
  • Notice
Read

Collaboration agreement concluded with Aichi Medical University.

  • 2019/10/08
  • Notice
Read

Notice of Office Relocation

  • 2019/05/30
  • Notice
Read

License Agreement concluded with Aligos Therapeutics, Inc.

  • 2019/01/22
  • Notice
Read

Our official website revamped.

  • 2018/12/14
  • Notice

Strategic cooperation agreement concluded with Open Circle Partners LLC.

  • 2018/09/02
  • Notice
Read

Oligonucleotides Therapeutics Discovery Collaboration Agreement concluded with Nissan Chemical Co., Ltd.

  • 2018/07/06
  • Notice
Read

Collaboration agreement concluded with the National Institute of Biomedical Innovation, Health and Nutrition (NIBIOHN).

  • 2018/04/02
  • Notice

Collaboration agreement concluded with Osaka University.

  • 2018/04/01
  • Notice

Investment from Osaka University Venture Capital Co., Ltd.

  • 2018/03/01
  • Notice
Read
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next

Luxna Biotech Co., Ltd.

  • C907 9F Bldg. C, Techno-Alliance Complex, 2-8 Yamadaoka, Suita, Osaka 565-0871 JAPAN
  • TEL: +81(0)6-6170-1228
  • FAX: +81(0)6-6170-2207
  • MAIL: info@luxnabiotech.co.jp
  • About
  • Oligonucleotide Therapeutics
  • Technology
  • Business Structure
  • News
  • Open Positions
  • Company Overview
  • Contact
  • Animal Experiments Policy
  • Privacy Protection Policy
  • Site Map

Copyright © 2018 Luxna Biotech Co., Ltd. All Rights Reserved.